3|3585|Public
50|$|The Warehouse {{distributed}} <b>basic</b> <b>pharmaceutical</b> <b>products</b> such as bismuth, iodine and bicarbonate, {{and also}} other commodities such as liquorice, spices and talcum powder. In 1908, the two partners established Gaetano Zambon & Co whose shares were divided equally between Gaetano, Silvio Farina and Teodorico Viero. In 1911, the business expanded {{over the entire}} region, forcing them to move to new offices.|$|E
40|$|This article {{analyses}} R&D, {{innovation and}} foreign trade {{activity of the}} chemical industry in the selected EU Member States. The paper examines the period from 2005 to 2015. The methodology {{is based on the}} application of key indicators in order to provide objective conclusions on work productivity and effectiveness of chemicals production and production of <b>basic</b> <b>pharmaceutical</b> <b>products</b> and preparations. The aim of this research is to analyse the European chemical industry from the aspect of R&D and innovation activity. The main research results include R&D, innovativeness, foreign trade activity results, the rank of technological position of the European chemical industry, and recommendations and proposals for enhancing innovation and international competitiveness. ...|$|E
40|$|B 05 - B 09 Mining and quarrying: {{of which}} CO 2 taxes Mining and quarrying: total energy taxes 201, 82 157, 23 176, 34 213, 82 266, 97 C 10 - C 12 Manufacture of food products, {{beverages}} and tobacco products 129, 6534996 197, 3047927 188, 601087 180, 7818602 220, 781289 C 13 - C 15 Manufacture of textiles, wearing apparel and leather products 60, 0753786 81, 23013721 69, 5465117 63, 80894203 72, 6581947 C 16 Manufacture of wood and of products of wood and cork, except furniture; manufacture of articles of straw and plaiting materials 60, 11823286 77, 46062476 68, 4445346 68, 43335366 99, 7627587 C 17 Manufacture of paper and paper products 35, 90947135 60, 03206935 27, 6695617 23, 77520947 39, 0469994 C 18 Printing and reproduction of recorded media 9, 16714493 8, 71699566 5, 49880576 5, 52770587 25, 9627712 C 19 Manufacture of coke and refined petroleum products 420, 7312433 566, 519275 589, 836281 567, 1010122 656, 078641 C 20 Manufacture of chemicals and chemical products 474, 7217931 537, 2332513 641, 717847 662, 3975237 750, 092938 C 21 Manufacture of <b>basic</b> <b>pharmaceutical</b> <b>products</b> and pharmaceutical preparations- 0 0 0 0 C 22 Manufacture of rubber and plastic products 23, 73999775 39, 54519622 47, 2625898 31, 11485427 52, 2323537 C 23 Manufacture of other non-metallic mineral products 292, 1987765 295, 8383594 282, 321637 265, 3400775 300, 53241...|$|E
40|$|Stability {{testing is}} a key aspect while formulating any <b>pharmaceutical</b> <b>product.</b> The {{photostability}} studies are conducted with main objective that appropriate light exposure does not leads to unacceptable changes in dosage form. Photo degradation leads to changes in Physical appearance as well as chemical composition of dosage form. The objective {{of the present study}} is to describe the approaches for the photostability studies on <b>pharmaceutical</b> <b>Products.</b> Also this review deals with the factors affecting the photostability of <b>pharmaceutical</b> <b>products</b> as well as certain examples of photostability studies on <b>pharmaceutical</b> <b>products</b> are also described...|$|R
5000|$|Yunnan Baiyao Group Co., Ltd is a Kunming-based {{company that}} conducts the research, {{development}} and manufacture of <b>pharmaceutical</b> <b>products</b> (mainly traditional Chinese medicine) {{as well as}} the wholesale and retail of outsourcing <b>pharmaceutical</b> <b>products.</b>|$|R
40|$|OBJECTIVE: To compile an {{inclusive}} list of Canadian <b>pharmaceutical</b> <b>products</b> available in 1991 that contained sulfites. DATA SOURCES: Written and oral responses from 94 pharmaceutical companies {{selected from the}} 1989 Compendium of Pharmaceuticals and Specialties. RESULTS: A list of sulfite-containing <b>pharmaceutical</b> <b>products</b> was compiled from data supplied by the 90 responding companies. Companies whose products contained no sulfites were separately identified. CONCLUSIONS: Sulfites are present in many <b>pharmaceutical</b> <b>products</b> and are one of many excipients and additives that {{have been reported to}} cause severe adverse reactions. The provided list should be a useful aid for health care practitioners when prescribing <b>pharmaceutical</b> <b>products</b> for sulfite-sensitive patients...|$|R
50|$|Freeze-drying is {{also used}} in {{manufacturing}} of raw materials for <b>pharmaceutical</b> <b>products.</b> Active <b>Pharmaceutical</b> <b>Product</b> Ingredients (APIs) are lyophilized to achieve chemical stability under room temperature storage. Bulk lyophilization of APIs is typically conducted using trays instead of glass vials.|$|R
40|$|Abstract: Most {{existing}} researches treated <b>pharmaceutical</b> <b>product</b> {{development process}} {{as a sort of}} “black box. ” This paper, however, will focus on the product development process to explore the organizational capabilities and effective development patterns. Interviews and statistical analyses with leading companies in Japanese pharmaceutical industry indicated that “go or no-go decision ” is the significant organizational capability, in fact differing among companies, which effects performances in <b>pharmaceutical</b> <b>product</b> development process. This organizational capability is accumulated through experiences in <b>pharmaceutical</b> <b>product</b> development projects...|$|R
40|$|The local {{application}} of <b>pharmaceutical</b> <b>products</b> may induce skin adverse reactions, including allergic contact dermatitis. Indeed, <b>pharmaceutical</b> <b>products</b> are, in general, applied on diseased or inflamed skin, the barrier function {{of which is}} often incapacitated, leading to enhanced skin penetration of the applied chemicals. Under these circumstances, even weak allergens are in such cases able to induce sensitization. The contact allergens in topical <b>pharmaceutical</b> <b>products</b> concern active principles and vehicle components, the latter of which are discussed in this article. status: publishe...|$|R
50|$|<b>Pharmaceutical</b> <b>products</b> Valsad Wyeth Lederle Ltd.|$|R
25|$|Canada - Patent Protection of <b>Pharmaceutical</b> <b>Products.</b>|$|R
50|$|This {{division}} {{imports and}} distributes <b>pharmaceutical</b> <b>products.</b>|$|R
50|$|Triazines {{are also}} found in <b>pharmaceutical</b> <b>products.</b>|$|R
5000|$|Sekpharma: vitamin {{supplements}} and other <b>pharmaceutical</b> <b>products</b> ...|$|R
5000|$|<b>Pharmaceutical</b> <b>Product</b> Development ($1.35B {{revenues}} in 2014), ...|$|R
5000|$|<b>Pharmaceutical</b> <b>products,</b> Vapi Sun <b>Pharmaceuticals,</b> SOHAM ACCOUNTING ...|$|R
5000|$|God, {{composed}} of a cabinet containing <b>pharmaceutical</b> <b>products.</b>|$|R
40|$|Patenting new <b>products</b> in <b>pharmaceuticals</b> {{industry}} is of greater importance {{than in the}} other high technology branches of industry nowadays. Concentration of manufacturing takes place in pharmaceuticals industry {{as well as in}} the other branches of industry and it is characterised by the joining of firms. However, there are several specific features in patenting <b>pharmaceutical</b> <b>products.</b> Enforcement of the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement) made it compulsory to establish in all World Trade Organization (WTO) Members patent protection on <b>pharmaceutical</b> <b>products</b> and their manufacturing methods as well as patent protection of drugs. WTO Doha Declaration is an essential stage in patent protection of <b>pharmaceutical</b> <b>products</b> establishing the legal basis and compulsory licensing system. In 2005, the European Commission completed the Regulation of the European Parliament and the Council on compulsory licensing of patents relating to the manufacture of <b>pharmaceutical</b> <b>products</b> for export to countries with public health problems. patent protection of <b>pharmaceutical</b> <b>products,</b> the TRIPS Agreement, the Doha Declaration, compulsory license, exclusive right, global economy...|$|R
30|$|It caters {{information}} about quality {{and safety of}} <b>pharmaceutical</b> <b>products.</b>|$|R
5000|$|Befol, a {{brand name}} <b>pharmaceutical</b> <b>product</b> {{containing}} diclofenac and pridinol ...|$|R
40|$|Examining {{the problem}} of realizing the right to health in {{accessible}} and affordable <b>pharmaceutical</b> <b>product,</b> this dissertation begins with the legal personality of the actors involved in {{the realization of the}} right to health. Chapter 2 further explores the uniqueness of <b>pharmaceutical</b> <b>products</b> and development of the pharmaceutical industry. Chapter 3 describes the development of intellectual property protection on <b>pharmaceutical</b> <b>products.</b> Chapter 4 then focuses on the international human rights development of the right to health and discusses the relationship of the right to health to accessible and affordable <b>pharmaceutical</b> <b>products.</b> Chapter 5 describes in greater detail the responsibility and accountability of the right and how international law should adapt to the global world. Lastly, Chapter 6 returns to {{the problem of}} the international human right to health and proposes a resolution to balance the interests...|$|R
40|$|This thesis {{examines}} the adjudication of <b>pharmaceutical</b> <b>product</b> liability claims under the Australian Consumer Law. Recognising the seminal role that policy and principles {{have in the}} interpretation of legislation, this thesis encourages the adoption of a principled approach in the adjudication of statutory <b>pharmaceutical</b> <b>product</b> liability claims in Australia. The principles can be used to critique the current adjudication of <b>pharmaceutical</b> <b>product</b> injury claims while also guiding the determination of future claims. This thesis demonstrates a step forward in streamlining the law in this area, thus fulfilling its objective to reform product liability law in Australia...|$|R
25|$|In <b>pharmaceutical</b> <b>products,</b> silica aids powder flow when tablets are formed.|$|R
50|$|Douglas Pharmaceuticals Ltd is a New Zealand-based {{manufacturer}} of <b>pharmaceutical</b> <b>products.</b>|$|R
50|$|The Hefame Group is a Spanish {{cooperative}} which distributes <b>pharmaceutical</b> <b>products.</b>|$|R
50|$|In <b>pharmaceutical</b> <b>products,</b> silica aids powder flow when tablets are formed.|$|R
5000|$|PEG is {{also used}} as an {{excipient}} in many <b>pharmaceutical</b> <b>products.</b>|$|R
50|$|The {{pharmaceutical}} {{industry in the}} United Kingdom directly employs around 72,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of <b>pharmaceutical</b> <b>products</b> from the UK totalled £14.6 billion, creating a trade surplus in <b>pharmaceutical</b> <b>products</b> of £4.3 billion.|$|R
5000|$|Specialty <b>Pharmaceuticals</b> <b>products</b> include branded {{drugs as}} well as {{specialty}} generics and active <b>pharmaceutical</b> ingredients (APIs). <b>Products</b> include biologics, medicinal opioids, synthetic controlled substances, and acetominophen.|$|R
5000|$|The {{combination}} diclofenac/misoprostol (trade name Arthrotec) is a <b>pharmaceutical</b> <b>product</b> that contains: ...|$|R
5000|$|Rosen, George, ed. Herbs and Herbals. Summit, NJ: Ciba <b>Pharmaceutical</b> <b>Products,</b> 1943.|$|R
50|$|Pfizer Limited of Sandwich, Kent for Research, {{development}} and manufacture of <b>pharmaceutical</b> <b>products.</b>|$|R
5000|$|... #Caption: Escherichia coli bacteria, {{which are}} often {{utilized}} in production of <b>pharmaceutical</b> <b>products.</b>|$|R
5000|$|... v To {{monitor and}} review the {{implementation}} of the legislation on <b>pharmaceutical</b> <b>products.</b>|$|R
5000|$|Handbook of Preformulation: Drugs, Botanicals and Biological <b>Pharmaceutical</b> <b>Products.</b> Boca Raton, FL: CRC, 2006[...]|$|R
5000|$|... {{to produce}} {{products}} intended for human therapeutic use (<b>pharmaceutical</b> <b>products</b> or tissue for implantation); ...|$|R
